1. Home
  2. ALAR vs ZNTL Comparison

ALAR vs ZNTL Comparison

Compare ALAR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$6.31

Market Cap

58.8M

Sector

Technology

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.59

Market Cap

156.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
ZNTL
Founded
2013
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
156.7M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ALAR
ZNTL
Price
$6.31
$2.59
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$27.00
$6.60
AVG Volume (30 Days)
39.0K
670.4K
Earning Date
03-19-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.87
EPS
N/A
N/A
Revenue
N/A
$67,425,000.00
Revenue This Year
$31.17
N/A
Revenue Next Year
$30.14
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.45
$1.01
52 Week High
$18.00
$3.95

Technical Indicators

Market Signals
Indicator
ALAR
ZNTL
Relative Strength Index (RSI) 39.31 50.40
Support Level N/A $1.29
Resistance Level $8.00 $2.69
Average True Range (ATR) 0.49 0.22
MACD -0.04 -0.01
Stochastic Oscillator 19.05 39.17

Price Performance

Historical Comparison
ALAR
ZNTL

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: